Advertisement
Canada markets closed

  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CAD/USD

    0.7283
    +0.0022 (+0.30%)
     

  • CRUDE OIL

    79.14
    +0.14 (+0.18%)
     

  • Bitcoin CAD

    79,655.84
    -2,970.02 (-3.59%)
     

  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     

  • GOLD FUTURES

    2,331.50
    +20.50 (+0.89%)
     

  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • NASDAQ futures

    17,495.50
    +57.25 (+0.33%)
     

  • VOLATILITY

    15.39
    -0.26 (-1.66%)
     

  • FTSE

    8,121.24
    -22.89 (-0.28%)
     

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • CAD/EUR

    0.6792
    -0.0010 (-0.15%)
     

Today's Research Reports on Centric Health, Fennec Pharmaceuticals, ProMIS Neurosciences and Theratechnologies

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / July 13, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Centric Health Corporation
https://rdinvesting.com/news/?ticker=CHH.TO

Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO

ProMIS Neurosciences, Inc.
https://rdinvesting.com/news/?ticker=PMN.TO

Theratechnologies Inc.
https://rdinvesting.com/news/?ticker=TH.TO

ADVERTISEMENT

Centric Health's stock moved 1.85% higher Thursday, to close the day at $0.275. The stock recorded a trading volume of 66,500 shares, which was below its three months average volume of 215,847 shares. In the last year, Centric Health's shares have traded in a range of 0.25 - 0.82. The stock is currently trading 66.46% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.291 is below its 200-day moving average of $0.416. Shares of Centric Health are trading at a Price to Earnings ratio of 13.75. Shares of Centric Health have fallen approximately 46.15 percent year-to-date.

Access RDI's Centric Health Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CHH.TO

On Thursday, shares of Fennec Pharmaceuticals recorded a trading volume of 700 shares, which was below the three months average volume of 2,892 shares. The stock ended the day 1.82% higher at 12.87. The share price has gained 81.27% from its 52 week low with a 52 week trading range of 7.10 - 18.86. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $14.09 is greater than its 200-day moving average of $13.60. Shares of Fennec Pharmaceuticals have gained approximately 3.04 percent year-to-date.

Access RDI's Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO

ProMIS Neurosciences' stock had no change Thursday, to close the day at $0.37. The stock recorded a trading volume of 129,227 shares, which was below its three months average volume of 222,034 shares. In the last year, ProMIS Neurosciences' shares have traded in a range of 0.18 - 0.73. The share price has gained 105.56% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.38 is below its 200-day moving average of $0.40. Shares of ProMIS Neurosciences have gained approximately 85 percent year-to-date.

Access RDI's ProMIS Neurosciences, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PMN.TO

On Thursday, shares of Theratechnologies recorded a trading volume of 147,544 shares, which was below the three months average volume of 216,430 shares. The stock ended the day 0.45% higher at 11.16. The share price has gained 125.00% from its 52 week low with a 52 week trading range of 4.96 - 14.75. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $13.09 is greater than its 200-day moving average of $9.98. Shares of Theratechnologies have gained approximately 55.43 percent year-to-date.

Access RDI's Theratechnologies Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TH.TO

Our Actionable Research on Centric Health Corporation (TSX:CHH.TO) and Fennec Pharmaceuticals Inc. (TSX:FRX.TO) and ProMIS Neurosciences, Inc. (TSX:PMN.TO) and Theratechnologies Inc. (TSX:TH.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address: Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email: contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com